Clinical trials: Androgen Deprivation Therapy
Prostate Cancer
A Prolonged Nightly Fasting for Men on ADT for PCa
This small study tested a 3-month text-based health coaching program for men with prostate cancer on hormone therapy. The program was feasible and well accepted, with participants showing good engagement and some improvements in…
- Trial name
- NCT07462403
- Testing
- Prolonged Nightly Fasting (PNF+), Healthy Diet Text Messaging
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Thomas Jefferson University
Prostate Cancer
S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01120262
- Testing
- gene expression analysis, polymorphism analysis, laboratory biomarker analysis
- Volunteers
- 545 people
- Sponsor
- SWOG Cancer Research Network
Cancer of Prostate, Cancer of the Prostate
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
This study will evaluate the feasibility, safety, and efficacy of intradermal vaccination of prostate cancer patients with alpha-type-1-polarized dendritic cells (DC1) loaded with apoptotic allogeneic tumor (LNCap).
- Conditions
- Cancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate, Neoplasms, Prostatic
- Trial name
- NCT00970203
- Testing
- androgen ablation (AA), DC1 vaccine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Roswell Park Cancer Institute
Castration Resistant Prostate Cancer (CRPC)
A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC
This is a prospective observational study to evaluate effectiveness and safety of Enzalutamide for Castration Resistant Prostate Cancer (CRPC) patients who decided to administer Enzalutamide after anti-androgen therapy.
- Trial name
- DELC (NCT02669147)
- Volunteers
- 160 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
PSMA PET/CT-Guided SBRT Plus Darolutamide in mHSPC
This is a multicenter, randomized, open-label phase 2 study for men with metastatic hormone-sensitive prostate cancer. About 254 participants will first receive 6 months of darolutamide plus androgen deprivation therapy.
- Trial name
- PSMA-DaroRT (NCT07649421)
- Testing
- Stereotactic Body Radiotherapy (SBRT), Darolutamide 600 mg twice daily, Androgen Deprivation Therapy (ADT)
- Where
- China
- Volunteers
- 254 people
- Sponsor
- West China Hospital
Prostate Cancer
Open-Label, Randomised Parallel-Group Study
An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy.
- Trial name
- NCT00728533
- Testing
- Degarelix
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00004124
- Testing
- bicalutamide, goserelin, mitoxantrone hydrochloride
- Where
- 234 sites in United States
- Volunteers
- 983 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
In this research study, we aim to evaluate the feasibility, toxicity and efficacy of early multimodality systemic therapy (a combination of docetaxe, bevacizumab, and androgen deprivation therapy(ADT) in men with biochemical…
- Trial name
- NCT00658697
- Testing
- Docetaxel, Bevacizumab, ADT
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Carcinoma
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
This phase III trial compares the effect of adding darolutamide to ADT versus ADT alone after surgery for the treatment of high-risk prostate cancer. ADT reduces testosterone levels in the blood.
- Trial name
- NCT04484818
- Testing
- Darolutamide, Goserelin Acetate, Leuprolide Acetate
- Where
- 115 sites in United States
- Volunteers
- 27 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Cancer of Prostate
Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP
This is a phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist (arm A) versus anti-androgen therapy (AAT) with…
- Trial name
- SAVE (NCT03899077)
- Testing
- Apalutamide, Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial, Goserelin Acetate 10.8 MG Subcutaneous Implant
- Where
- 9 sites in Belgium
- Volunteers
- 202 people
- Sponsor
- Cancer Research Antwerp
High Risk Prostate Carcinoma
Towards Optimal Treatment for High Risk Prostate Cancer
The goal of this clinical trial is to combine several optimized treatments of high risk prostate cancer. The main question to answer is: is it safe to combine these optimized treatments.
- Trial name
- HYPOPRIME (NCT06204341)
- Testing
- HYPOPRIME treatment
- Where
- Netherlands
- Volunteers
- 207 people
- Sponsor
- Haaglanden Medical Centre
Prostate Cancer, Bone Metastases
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Newly diagnosed metastatic prostate cancer subjects with bone metastases will be accrued to this stratified randomized 2-arm Phase II trial. Subjects will be randomized 1:2 to ADT or ADT with Radium-223 dichloride respectively.
- Conditions
- Prostate Cancer, Bone Metastases, Prostate Neoplasms
- Trial name
- NCT02582749
- Testing
- LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- Ajjai Alva, MD
Prostate Cancer
The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer
Thirty-five men with newly diagnosed, metastatic prostate cancer are scanned with 18F-PSMA 1007 PET/CT at baseline, 3 weeks after the initiation of GnRH-antagonist, at one year and at the time of castration resistant prostate…
- Trial name
- ADTPSMA2 (NCT03876912)
- Testing
- GnRH antagonist
- Where
- Finland
- Volunteers
- 35 people
- Sponsor
- Turku University Hospital
Prostate Adenocarcinoma
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
This phase 2 trial studies radium Ra 223 dichloride, hormone therapy and stereotactic body radiation in treating patients with prostate cancer that has spread to other places in the body.
- Trial name
- NCT03361735
- Testing
- Leuprolide Acetate, Goserelin Acetate, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer
Propranolol Combined With Novel Endocrine Therapy and Androgen Deprivation Therapy (ADT) for Neoadjuvant Treatment in High-Risk Prostate Cancer Patients: A Multicenter, Single-Arm Clinical Study
Propranolol, a non-selective adrenergic beta-receptor blocker, is conventionally used to treat arrhythmias. However, recent studies have demonstrated its therapeutic efficacy in breast cancer, prostate cancer, neonatal…
- Trial name
- NCT07311915
- Testing
- Propranolol combined with novel endocrine therapy and androgen deprivation therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhongda Hospital
Prostate Cancer, Physical Activity
An Exercise Intervention for Prostate Cancer Patients Receiving Androgen Deprivation Therapy
This main purpose of this study is to examine the effects of an exercise intervention to counteract adverse side effects related to Androgen Deprivation Therapy (ADT) in prostate cancer patients.
- Conditions
- Prostate Cancer, Physical Activity, Side-effects
- Trial name
- MIGHTY (NCT02248350)
- Testing
- Supervised and Home Based Exercise, Stretching Control Group
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Georgetown University
Prostate Cancer
Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer
This is an open-label, multi-centre single arm trial to investigate efficacy and safety of degarelix in Korean patients with prostate cancer for bridging between CS21 trial (NCT00295750) results.
- Trial name
- NCT01071915
- Testing
- Degarelix 240/80 mg
- Where
- 11 sites in South Korea
- Volunteers
- 157 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Folate Study in Men With Advanced Prostate Cancer
The researchers hope to learn if Trimethoprim, 150mg taken daily for 3 months, is a safe and effective way to reduce folate levels at time of Androgen Deprivation Therapy (ADT) in men with advanced prostate cancer.
- Trial name
- NCT06536374
- Testing
- Trimethoprim Tablets
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Prostate Cancer
Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer
This is a randomized study to evaluate the efficacy and safety neoadjuvant androgen deprivation therapy with goserelin and abiraterone with or without apalutamide prior to radical prostatectomy for patients diagnosed with…
- Trial name
- NCT02789878
- Testing
- Goserelin, Prednisone, Abiraterone
- Where
- Brazil
- Volunteers
- 64 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Prostate Cancer
Xbox Kinect Training in Men With Prostate Cancer
The purpose of this study is to investigate the effect of 12 weeks systematically training using the Xbox Kinect system. Outcome measures are made on physical function, quality of life, fatigue and metabolic parameters.
- Trial name
- NCT01762241
- Testing
- Home based training using the Xbox Kinect system
- Where
- 3 sites in Denmark
- Volunteers
- 46 people
- Sponsor
- Hospitalsenheden Vest